Industry analysts at NeuroTech Analytics project a total addressable market (TAM) of $2.3 billion for high-density closed-loop BCIs by 2030. ANX-131 is expected to capture roughly 18% of that market, primarily in the epilepsy and post-stroke rehabilitation sectors.
In the rapidly evolving landscape of neurotechnology, few identifiers have generated as much quiet speculation among industry insiders as . While the general public has become fixated on consumer-grade wearables and brain-computer interfaces (BCIs) for gaming, a more sophisticated, clinical-grade architecture has been emerging from the R&D shadows. ANX-131 is not just another electrode array; it represents a paradigm shift in how we approach bidirectional neural communication.